Neurocrine Biosciences, Inc.
NBIX
$151.39
-$1.09-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.68B | 2.51B | 2.41B | 2.36B | 2.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.68B | 2.51B | 2.41B | 2.36B | 2.24B |
| Cost of Revenue | 986.90M | 925.90M | 870.60M | 765.10M | 716.20M |
| Gross Profit | 1.70B | 1.58B | 1.54B | 1.59B | 1.53B |
| SG&A Expenses | 1.16B | 1.10B | 1.05B | 1.02B | 938.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.14B | 2.02B | 1.93B | 1.79B | 1.65B |
| Operating Income | 539.60M | 485.10M | 487.40M | 569.00M | 588.30M |
| Income Before Tax | 628.60M | 527.10M | 466.20M | 486.00M | 521.60M |
| Income Tax Expenses | 200.60M | 178.80M | 160.40M | 144.70M | 135.70M |
| Earnings from Continuing Operations | 428.00 | 348.30 | 305.80 | 341.30 | 385.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 428.00M | 348.30M | 305.80M | 341.30M | 385.90M |
| EBIT | 539.60M | 485.10M | 487.40M | 569.00M | 588.30M |
| EBITDA | 569.30M | 513.60M | 515.90M | 596.10M | 614.00M |
| EPS Basic | 4.30 | 3.48 | 3.04 | 3.39 | 3.86 |
| Normalized Basic EPS | 3.94 | 3.58 | 3.59 | 4.10 | 4.22 |
| EPS Diluted | 4.18 | 3.38 | 2.95 | 3.29 | 3.74 |
| Normalized Diluted EPS | 3.83 | 3.49 | 3.48 | 3.98 | 4.08 |
| Average Basic Shares Outstanding | 398.10M | 399.80M | 401.60M | 401.70M | 400.10M |
| Average Diluted Shares Outstanding | 408.90M | 410.70M | 413.60M | 414.70M | 414.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |